<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138538</url>
  </required_header>
  <id_info>
    <org_study_id>MS100015_0019</org_study_id>
    <nct_id>NCT03138538</nct_id>
  </id_info>
  <brief_title>M8891 First in Human in Solid Tumors</brief_title>
  <acronym>M8891</acronym>
  <official_title>An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD), safety,
      tolerability, Pharmacokinetic and antitumor activity of M8891 as single agent in subjects
      with solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Anticipated">July 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the DLT period</measure>
    <time_frame>From Cycle Day 1 up to Cycle 1 Day 21</time_frame>
    <description>DLTs are defined as any pre-defined set of adverse events (AEs) which are defined in the protocol, observed in the first 21-day treatment cycle and judged to be M8891 related or clinically relevant (excluding events to be related to underlying disease, medical history or concomitant medications/ procedures in the opinion of the safety monitoring committee).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation and Death</measure>
    <time_frame>Up to 7 months</time_frame>
    <description>AE is defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE is any untoward medical occurrence that at any dose results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or considered medically important.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Significant Changes in Laboratory, Electrocardiogram measures, vital signs, Eastern Cooperative Oncology Group Performance status (ECOG PS)</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Clinical laboratory assessments will include hematology, biochemistry and coagulation parameters. Vital sign assessments will include assessments of heart rate, diastolic blood pressure, systolic blood pressure, weight and temperature, ECG and ECOG PS will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Cmax will be obtained directly from the concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Time to reach the maximum plasma concentration (Tmax) will be obtained directly from the concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration is at or above the lower limit of quantification (LLQ). AUC0-t will be to be calculated according to the mixed log-linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>AUC0-inf will be calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve within one dosing interval (AUC0-tau) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>AUC 0-tau is defined as the area under the concentration-time curve from 0 to dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Terminal half-life is the time measured for the concentration of drug to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance From Plasma Following Extravascular Administration (CL/f) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution Following Extravascular Administration of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Apparent Terminal Rate Constant is defined as the rate at which drug is cleared from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio for AUCtau (Racc(AUCtau)) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Accumulation ratio will be calculated from AUCtau at steady state and AUCtau after single dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio for Cmax (Racc(Cmax))of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Accumulation ratio will be calculated from Cmax at steady state and Cmax after single dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance of Drug Following Extravascular Administration at Steady State (CLss/F) of M8891</measure>
    <time_frame>Day 1, 2, 8, 15, 16 of Cycle 1; Day 1 of Cycle 2 and Cycle 3</time_frame>
    <description>Clearance (CLss/F) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Time from date of randomization up to end of the treatment or until disease progression (assessed up to 8 months)</time_frame>
    <description>BOR will be determined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by investigators. BOR is defined as the best response of any of the complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) recorded from the date of randomization until disease progression. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)=Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Benefit</measure>
    <time_frame>Time from date of randomization up to end of the treatment or until disease progression (assessed up to 8 months)</time_frame>
    <description>Clinical benefit defined as Complete Response [CR], Partial Response [PR] or Stable Disease [SD] for &gt;= 12 weeks. Clinical benefit will be assessed according to RECIST Version 1.1. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Progressive disease (PD) :defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from date of randomization until disease progression or death (assessed up to 8 months)</time_frame>
    <description>Progression-free survival time (PFS) is defined as the time from first study drug administration to either first observation of disease progression (as assessed by RECIST v 1.1) or occurrence of death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>M8891</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M8891</intervention_name>
    <description>Subjects will receive M8891 orally once daily or twice daily at escalated dose levels for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.</description>
    <arm_group_label>M8891</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be refractory to or intolerant of existing cancer therapy(ies) known to
             provide clinical benefit.

          -  Histologically confirmed advanced solid tumors with no clear curative treatment
             options available after at least 1 prior systemic anticancer therapy.

          -  Tumor accessible for biopsies and agreement to conduct pre-dose and post-dose fresh
             tumor biopsies.

          -  Male or female subjects at least 18 years of age.

        Exclusion Criteria:

          -  ECOG PS &gt;= 2

          -  Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone
             marrow/stem cell transplantation within 5 years of study start.

          -  Severe bone marrow, renal or liver impairment.

          -  Presence of deep vein thrombosis based on screening lower extremity Doppler
             ultrasonography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Research &amp; Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Smilow Cancer Hospital - Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert O'Neil, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center - Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205-1911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>M8891</keyword>
  <keyword>Methionine Aminopeptidase 2 Inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

